학술논문
Restless legs syndrome is a relevant comorbidity in patients with inflammatory bowel disease
Original Article
Original Article
Document Type
Academic Journal
Author
Source
International Journal of Colorectal Disease. July 2018, Vol. 33 Issue 7, p955, 8 p.
Subject
Language
English
ISSN
0179-1958
Abstract
Author(s): Janek Becker [sup.1], Felix Berger [sup.1], Katharina A. Schindlbeck [sup.2] [sup.3], Denis Poddubnyy [sup.1], Peter M. Koch [sup.2], Jan C. Preiß [sup.1] [sup.4], Britta Siegmund [sup.1], Frank Marzinzik [sup.2], [...]
Background and aims In patients with inflammatory bowel disease (IBD), restless legs syndrome (RLS) may occur as an extraintestinal disease manifestation. Iron deficiency (ID) or folate deficiency/vitamin B.sub.12 deficiency (FD/VB.sub.12D) has previously been described to cause RLS. Here, we determined the prevalence and severity of RLS in IBD patients and evaluated the effect of iron and/or folic acid/vitamin B.sub.12 supplementation. Methods Patients were screened for ID and RLS by a gastroenterologist. If RLS was suspected, a neurologist was consulted for definitive diagnosis and severity. Patients with RLS and ID, FD, or VB.sub.12D received supplementation and were followed-up at weeks 4 and 11 after starting supplementation. Results A total of 353 IBD patients were included. Prevalence for RLS was 9.4% in Crohn's disease (CD) and 8% in ulcerative colitis (UC). Prevalence for the subgroup of clinically relevant RLS (symptoms [greater than or equal to] twice/week with at least moderate distress) was 7.1% (n = 16) for CD and 4.8% (n = 6) for UC. 38.7% of RLS patients presented with ID, FD, and/or VB.sub.12D. Most frequently ID was seen (25.8%; n = 8). Iron supplementation resulted in RLS improvement (p = 0.029) at week 4 in seven out of eight patients. Conclusion Although the overall prevalence of RLS in IBD did not differ to the general population, clinically relevant RLS was more frequent in IBD patients and, therefore, it is important for clinicians to be aware of RLS symptoms. Though for definite diagnosis and proper treatment of RLS, a neurologist must be consulted. Additionally, iron supplementation of IBD patients with ID can improve RLS symptoms. Trial registration ClinicalTrials.gov No. NCT03457571
Background and aims In patients with inflammatory bowel disease (IBD), restless legs syndrome (RLS) may occur as an extraintestinal disease manifestation. Iron deficiency (ID) or folate deficiency/vitamin B.sub.12 deficiency (FD/VB.sub.12D) has previously been described to cause RLS. Here, we determined the prevalence and severity of RLS in IBD patients and evaluated the effect of iron and/or folic acid/vitamin B.sub.12 supplementation. Methods Patients were screened for ID and RLS by a gastroenterologist. If RLS was suspected, a neurologist was consulted for definitive diagnosis and severity. Patients with RLS and ID, FD, or VB.sub.12D received supplementation and were followed-up at weeks 4 and 11 after starting supplementation. Results A total of 353 IBD patients were included. Prevalence for RLS was 9.4% in Crohn's disease (CD) and 8% in ulcerative colitis (UC). Prevalence for the subgroup of clinically relevant RLS (symptoms [greater than or equal to] twice/week with at least moderate distress) was 7.1% (n = 16) for CD and 4.8% (n = 6) for UC. 38.7% of RLS patients presented with ID, FD, and/or VB.sub.12D. Most frequently ID was seen (25.8%; n = 8). Iron supplementation resulted in RLS improvement (p = 0.029) at week 4 in seven out of eight patients. Conclusion Although the overall prevalence of RLS in IBD did not differ to the general population, clinically relevant RLS was more frequent in IBD patients and, therefore, it is important for clinicians to be aware of RLS symptoms. Though for definite diagnosis and proper treatment of RLS, a neurologist must be consulted. Additionally, iron supplementation of IBD patients with ID can improve RLS symptoms. Trial registration ClinicalTrials.gov No. NCT03457571